Suksdorfin

CAS No. 53023-17-9

Suksdorfin( —— )

Catalog No. M36274 CAS No. 53023-17-9

Suksdorfin has hypoglycemic effects, promotes adipocyte differentiation and enhances lipocalin production, activates peroxisome proliferator-activated receptor gamma (PPARγ), promotes insulin-dependent glucose uptake by adipocytes, and can be used to study obesity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 445 Get Quote
5MG 686 Get Quote
10MG 938 Get Quote
25MG 1398 Get Quote
50MG 1822 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Suksdorfin
  • Note
    Research use only, not for human use.
  • Brief Description
    Suksdorfin has hypoglycemic effects, promotes adipocyte differentiation and enhances lipocalin production, activates peroxisome proliferator-activated receptor gamma (PPARγ), promotes insulin-dependent glucose uptake by adipocytes, and can be used to study obesity.
  • Description
    Suksdorfin has hypoglycemic effects, promotes adipocyte differentiation and enhances lipocalin production, activates peroxisome proliferator-activated receptor gamma (PPARγ), promotes insulin-dependent glucose uptake by adipocytes, and can be used to study obesity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    PPAR
  • Recptor
    PPAR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    53023-17-9
  • Formula Weight
    388.41
  • Molecular Formula
    C21H24O7
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O(C(CC(C)C)=O)[C@@H]1C=2C3=C(C=CC2OC(C)(C)[C@@H]1OC(C)=O)C=CC(=O)O3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • (R)-(+)-Bay-K-8644

    (R)-(+)-Bay-K-8644 is a Ca2+ channel and dihydropyridine agonist that inhibits Ba2+ currents (IBa), induces central respiratory depression in cats, and inhibits platelet activation through competitive antagonism of thromboxane A2-prostaglandin H2 receptors.

  • Aleglitazar

    A potent and balanced dual PPARα/γ agonist (EC50= 50/21 nM).

  • Oroxin A (b)

    Oroxin A is a partial PPARγ agonist that can activate PPARγ transcriptional activation in vitro and in vivo. Oroxin A also exhibited inhibitory activity against α-glucosidase and antioxidant capacity.